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A TASTE OF HOME FOR THE HOLIDAYS: PROVIDING A TRADITIONAL
HOLIDAY DINNER FOR INPATIENT STEM CELL TRANSPLANT PATIENTS
AND CAREGIVERS
Doyle, K. MD Anderson Cancer Center, Houston, TX
Background: Patients and caregivers undergoing hematopoietic
stem cell transplants (SCT) commit to long hospital stays, often last-
ing up to four weeks. During this time, patients, familymembers, and
caregivers are temporarily located in places other than their home
towns. This presents emotional, financial, and family challenges.
Holidays away from home are especially difficult, and may contrib-
ute to anxiety and depression.
Intervention: To support patients and caregivers who are away
from home and family, a large, comprehensive cancer center holds
a dinner between the major holidays of Thanksgiving and Christ-
mas. This has been a yearly event for the past 15 years. The din-
ner is planned, funded, and produced by the staff and aims to
provide a sense of home. The staff hosts fundraisers throughout
the year to support the dinner. The menu consists of both catered
and home-cooked dishes, mimicking the traditional American
holiday dinner. Staff members volunteer to set up, serve, and
clean up.
Evaluation: The holiday dinner has been beneficial for all who are
involved. Staff participation boosts morale and team spirit. Patients
and their caregivers are able to celebrate the holidays with their tem-
porary staff and fellow patient and caregiver family. The expressions
of heartfelt thanks and gratitude for the thoughtful efforts of the
staff, are almost overwhelming. Specific patient, caregiver, and staff
feedback will be shared.
Discussion: The annual holiday dinner serves as a means to pro-
vide patients and caregivers a dedicated time for social interaction
and a sense of normalcy during the stem cell transplant process.
Benefits of the holiday dinner for both patients and staff have as-
sured that the tradition has been passed on for 15 years, and will
continue.318
CYTOMEGALOVIRUS INFECTION OCCURRING BEFORE ENGRAFTMENT IN
RECIPIENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANS-
PLANTATION FROM ALTERNATIVE DONORS
Cozzi, J., Basso, A., Saslavsky, J., Saslavsky, M., Prone, L. CETRAMOR
BMT-Unit, Rosario, Santa Fe, Argentina
Background: Cytomegalovirus (CMV) remains an important infec-
tious cause of morbidity and mortality among allogeneic Haema-
topoietic Stem Cell Transplantation (aHSCT) recipients (r).
CMV-seropositive r of transplants from alternative (A) donors are
at higher risk for very early onset of CMV infection (I) and disease
(D). Quantitative (q) polymerase chain reaction (PCR) assay for
CMVDNA in whole (W) blood (B) samples (S) is useful in identifing
patients (p) at risk for CMV-D before engraftment (E).
Methods: From 10/2008 to 10/2011 21 p who underwent A donor
aHSCT were studied. p in this cohort were tested bi-weekly by
qPCR assay for CMV DNA in WBS with a threshold for preemp-
tive (P) therapy (Th) at 500 copies (c)/ml (limit of detection). P Th
pre-E was started on IV foscarnet (F) 60 mg/Kg twice daily 14 days
as induction Th, followed by maintenance Th with 90 mg/Kg once
daily dosing until routine surveillance testing was negative. Age,
median (range) 28 (3-54) years. Male sex: 12 p (57%). Underlying
diseases: AML (6 p), ALL (6 p), CML (2 p), SAA (2 p), Inherited
Disorders of Metabolism (2 p), CMML (1 p), NHL (1 p), HL (1
p). D state at time of transplant: Refractory D: 12 p (57%),
CR.2nd: 5 p (24%). Conditioning Regimen: Reduced Intensity:
13 p (62%), Myeloablative: 8 p (38%). TBI (5 p)/TLI (8 p): 13p (62%). ATG (8 p)/CAMPATH-1H (3 p): 11 p (52%). Donors
Matched Unrelated (U): 5 p, Mismatched (MM) U: 6 p, MM
Related: 5 p, MM Umbilical Cord Blood (UCB): 5 p. Graft source:
peripheral blood stem cells: 16 p (76%), UCB: 5 p (24%). Graft-
versus-host disease (GVHD) prophylaxis: Cyclosporine + Myco-
phenolate Mofetil: 12 p (57%). Hyperacute GVHD 2 p (9,5%)
requiring high-doses corticosteroids. Acyclovir was given to Herpes
Simplex Virus seropositive r from the start of conditioning. CMV
serostatus: D+/R+: 12 p (57%), D-/R+: 9 p (43%). E was defined as
3 consecutive days with an absolute neutrophil (N) count .500
cells/uL.
Results: The median (range) time to N E was 19 (9-41) days. 8 p
(38%) developed CMV reactivation (R) prior to E. The median
(range) time to CMV-R was 12 (3-26) days. The median (range)
initial viral load in those p who developed CMV-R was 3.000
(500-10.000) c/ml. IV F was instituted as P antiviral Th in all p
who developed CMV-I pre-E. 1 p (4,8%) developed CMV-D (en-
cephalitis). None of these p died of CMV-D. F Th was not discon-
tinued in any p because of adverse effects.
Conclusion: Our study shows that a P treatment strategy based on
qPCR tests surveillance is safe and effective for treating CMV-I
ocurring before E in recipients of aHSCT from A donors.319
TRANSFUSION OF RED CELLS IN HEMATOPOIETIC STEM CELL TRANS-
PLANTATION: THE TRIST STUDY
Tay, J.1,2, Tinmouth, A.2, Fergusson, D.2, Allan, D.1 1Ottawa Hospital,
Ottawa, ON, Canada; 2University of Ottawa and Clinical Epidemiology
Program, Ottawa, ON, Canada
Background: Insight regarding transfusion practices inHematopoi-
etic Stem cell Transplantation (HSCT) are lacking, and the impact
of red blood cell (RBC) transfusion on outcomes following HSCT
are not well appreciated. A randomized study of transfusion is
required to gain insight on best transfusion practices in this
population.
Methods: In preparation for our trial, all adult transplant centres
associated with the Canadian Blood and Marrow Transplant Group
(CBMTG)(n 5 15) were asked to respond to a survey regarding
transfusion thresholds. Fourteen centres routinely transfuse 2 units
of RBCs when the hemoglobin\80 g/L and/or in response to pa-
tient specific indications while one centre transfuses RBCs when
the hemoglobin \70 g/L. The rationale for the near universal
adoption of red cell transfusion trigger of 80 g/L remains unclear.
Our centre has historically adopted a red cell transfusion trigger of
80 g/L and we conducted an audit of our practices for the year
2009. Despite our established trigger of 80 g/L, RBC transfusions
above this trigger occurred in 50% of all transplant patients ever
requiring red cells within the 1st 100 days of the transplant.
Further, 20% of all RBC transfusions occurred above the stated
trigger.
Results: Two of 5 invited CBMTG centres declined participation
for logistical reasons. In 3 centres, 100 patients undergoing HSCT
will be randomized to either a restrictive (target hemoglobin of 70-
90g/L) or liberal (target hemoglobin of 90-110g/L) RBC transfu-
sion strategy, based on daily hemoglobin values up to 100 days
post-transplant. The primary goal is to demonstrate study feasibil-
ity while collecting clinical outcomes on 1) Transfusion Require-
ments, 2) Transplant Related Mortality, 3) Maximum grade of
acute Graft versus Host Disease, 4) Veno-occlusive Disease, 5) Se-
rious Infections, 6) Bearman Toxicity Score, 7) Bleeding, 8) Qual-
ity of Life, 9) Number of Hospitalizations and Intensive Care Unit
admissions. At the time of writing, 25 patients have been followed
for 28 days post HSCT, with our 1st Data Safety Monitoring
Board review pending.
Conclusion: No CBMTG centre has clearly embraced a liberal
transfusion strategy and only 1 centre has embarked on a more re-
strictive strategy. This indicates some relative uncertainty with re-
gards to the benefits and harms of RBC transfusion in the HSCT
population. Upon completion, this pilot trial will provide
S324 Poster Session Ipreliminary insight into RBC transfusion practice and its influence
on HSCT outcomes.320
NEPHROTOXICITY OF CONCOMITANT ADMINISTRATION OF TACROLI-
MUS AND NEPHROTOXIC ANTIMICROBIAL AGENTS (AMINOGLYCOSIDES
AND GLYCOPEPTIDES) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Mori, T., Kato, J., Yamane, A., Okamoto, S. Keio University School of
Medicine, Tokyo, Japan
Background: Tacrolimus has been widely used for the prophylaxis
or treatment of graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem cell transplantation (allo-HSCT). Nephrotoxi-
city is one of its most important toxicities. Recipients of all-HSCT
are highly susceptible to infectious complications and are often
treated with nephrotoxic antimicrobial agents such as aminoglyco-
sides (AGs) and glycopeptides (GPs). Since nephrotoxicity of con-
comitant use of tacrolimus and these nephrotoxic agents has yet to
be fully and systematically evaluated, we retrospectively evaluated
it in the recipients of allo-HSCT.
Patients &Methods: Recipients of allo-HSCT who received in-
travenous AGs or GPs during the continuous intravenous infu-
sion of tacrolimus within 30 days after transplantation were
selected from the data base and 50 patients were included. Pa-
tients who received liposomal amphotericin-B or foscarnet were
excluded. The data including patient characteristics, whole blood
concentration of tacrolimus, dose and duration of AG/GP treat-
ment, and serum creatinine (sCr) were evaluated. Therapeutic
drug monitoring of AGs, GPs, and tacrolimus was performed
in all the patients.
Results: Median age of the patients was 47.5 years (range: 18-60)
and diagnoses were all hematological diseases. In the 50 patients,
there were 40 episodes of tacrolimus concomitant with AGs (amika-
cin, gentamicin, arbekacin) and 38 with GPs (teicoplanin, vancomy-
cin). Median duration of the concomitant administration with
tacrolimus was 8 days (range: 2-22) for AGs and 11.5 days (range:
4-40) for GPs. Mean blood concentrations of tacrolimus during
AG and GP administration were 17.162.1 and 16.261.6 mg/ml, re-
spectively. Twice or greater increases of sCr compared with that be-
fore initiating AGs or GPs were observed only in 2 of 40 (5.0%)
episodes with AGs and 1 of 38 (2.8%) with GPs. Nephrotoxicity
was reversible and manageable in all cases and no patient required
hemodialysis.
Conclusion: Concomitant administration of tacrolimus and AGs or
GPs is feasible even in the early post-transplant period.However, ap-
propriate management with therapeutic drug monitoring for each
agent is essential.321
FACTORS ASSOCIATED WITH THE AVOIDANCE OF RED CELL TRANSFU-
SION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kekre, N.1, Christou, G.1, Mallick, R.3, Tokessy, M.2, Tinmouth, A.1,
Tay, J.1, Allan, D.1,4 1University of Ottawa, Ottawa, ON, Canada;
2The Ottawa Hospital, Ottawa, ON, Canada; 3Ottawa Hospital Research
Institute, Ottawa, ON, Canada; 4Ottawa, ON, Canada
Background: Red blood cell (RBC) transfusion is required fre-
quently for most patients following hematopoietic stem cell trans-
plantation (HSCT). RBC transfusion, however, can be associated
with adverse events including transfusion reactions, acquiring trans-
missible disease and delayed recovery. Factors associated with avoid-
ance of transfusion are not well documented.
Study Design and Methods: Data concerning RBC transfusions
between day 0 and day +30 were analyzed for patients undergoing
HSCT at a single Canadian transplant centre between January
2002 and December 2007.Results: Of 555 patients undergoing HSCT with complete RBC
transfusion data, 59 patients (10.6%) did not require RBC trans-
fusion in the first 30 days after HSCT. Univariate analysis showed
no significant difference in age, graft source or conditioning reg-
imen between transfused compared with non-transfused patients.
Factors that were significantly associated with avoidance of trans-
fusion included male gender (p 5 0.0013), diagnosis (p\ 0.0001),
early stage disease (p 5 0.006) and higher baseline haemoglobin
(Hb) at time of transplant (p\ 0.0001). In multivariate analysis,
higher pre-transplant Hb, OR 9.73 (4.11, 23.02), and early stage
disease, OR 2.24 (1.05, 4.76), remained significantly associated
with avoidance of RBC transfusion. The degree of RBC transfu-
sion correlates with the pre-transplant Hb value (r 5 - 0.89). In
particular, a pre-transplant hemoglobin level of 114 g/L or
greater was most strongly associated with the avoidance of RBC
transfusion.
Conclusion: Increased pre-transplant Hb and early stage disease are
associated with avoidance of RBC transfusion afterHSCT. Interven-
tions aimed at improving pre-transplant hemoglobin levels require
further study.CRP–DATA MANAGEMENT322
PART-TIME EMPLOYMENT OF GRADUATE STUDENTS FOR CIBMTR DATA
SUBMISSION IS HIGHLY EFFICIENT AND MUTUALLY ADVANTAGEOUS
Rudolph, S., Salzman, D., Gazi, M., Vaughan, W.P., Koralkar, R. Uni-
versity of Alabama at Birmingham, Birmingham, AL
The Bone Marrow Transplantation & Cellular Therapy Program
and the School of PublicHealth,Department of Epidemiology at the
University of Alabama at Birmingham, has partnered with first year
Master candidates for completion and submission of stem cell recip-
ients’ CIBMTR forms. Both the transplant program and the students
have benefited from this collaboration.
Resource Management: The Adult Program averages 100 trans-
plant patients per year and this requires 2 full-time equivalents for
timely completion of CIBMTR forms. In this capacity, the Program
currently employs 1 full-time equivalent. The second position em-
ploys a Graduate Student Assistant in an irregular part-time position
without benefits, and performs identical data retrieval and entry
duties.
Time Utilization: The Graduate Student Assistant’s time is
scheduled around their classes with both morning and evening
work hours available. This schedule can be easily accommodated
as the School of Public Health is located only three blocks from
the Hospital.
Benefits: Benefits for the students exceed simple financial compen-
sation and are outlined below. Likewise the transplant program ben-
efits from these highly motivated individuals.
Student-
$ Financial pay comparative to entry level FTE
$ Potential internships within UAB Hospital
$ Project management skills attained
$ Data analysis skills
$ Process improvement participation
$ Abstracts/Publications
$ Easy accessibility between work and school
$ Program Director recommendation for desired careers (exam-




$ Cost savings-full-time vs. irregular part time without benefits
$ Data analysis assistance
$ Research assistance
$ Enhanced computer skills of a master level student
$ Generally highly efficient and goal oriented employees
Future Goals: Exit interviews to survey students’ satisfaction, ed-
ucational benefits and skills enhancement.
